Search

Blog

We constantly analyse the legislation and regulatory information related to a specific medicine in order to appraise the context in which the company operates

We put all our knowledge into play to anticipate risks and seize every opportunity, but above all to understand the rules of the game and display our creativity with them. We spread material and information proceeding from our investigation into medicines governance and regulatory science. In fact, we deem it necessary to be aware of the complexity of the results of research, regulation and drug policy in order to be able to work in a cultural ecosystem aiming both at promoting research outcomes that are useful to patients and at encouraging politicians to protect people’s health. The wider the knowledge of each interest group, the greater their ability to interact and achieve transparency of procedures and health protection.

  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value
All
  • All
  • Scenario analysis
  • Notes
  • Drug Policy
  • Rare Diseases
  • Mapping
  • Team Pharma Value

Towards the reform of governance of the Italian Medicines Agency and the Single Committee

This is our English version of the analysis 'Towards the reform of governance of the Italian Medicines Agency and the Single Committee' ...
Read more "

Pharma Value Agenda 2023

Il tema dell’agenda Pharma Value 2023 è “soldi e valore”. L’agenda di quest’anno è il frutto di un lavoro collettivo di tutto ...
Read more "

Nomos Pharma Value SPECIAL No. 2: AIFA reform - scenario and next steps

Nomos e Pharma Value hanno sviluppato un documento di approfondimento per analizzare la riforma di AIFA definita nelle scorse settimane al Senato ...
Read more "
Ispor November 2022

Timing of access to drugs and advanced therapies (ATMP) for ultra-rare diseases

Martedì 29 novembre 2022 Ginevra Mastroianni, Institutional and Regulatory Affairs Specialist di Pharma Value, ha presentato all’8° Congresso Nazionale dell’ISPOR Italy – ...
Read more "
Master DRMKA Novara

15 years of the DRMKA Master, a TEDx on regulatory and market access activities

Venerdì 14 ottobre 2022 Valeria Viola ha partecipato con un TEDx all’evento organizzato dal professor Armando Genazzani per i 15 anni del ...
Read more "

AIFA Business Plan 2022

ll 28 settembre 2022 la Conferenza Stato Regioni ha rinviato il parere (punto 7) per il Piano attività di AIFA 2022. Il piano individua 3 mission ...
Read more "

Unconventional team building

Dal 20 al 22 settembre 2022 i team di Pharma Value e di MA Provider SUMA (Start up Market Access) si sono ...
Read more "

New simplified P&R negotiation procedures

Nel 2020 AIFA ha introdotte le nuove procedure semplificate in materia di negoziazione P&R: procedura semplificata di prezzo e rimborso per la ...
Read more "

10 years of Pharma Value

23 giugno 2022, Lian Club, il barcone sul Tevere, nel cuore di Roma, la città dove avviene quasi tutto ciò che riguarda ...
Read more "
en_GB